|
Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) DCF-Bewertung |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) Bundle
Bewerten Sie die finanzielle Aussichten von Yunnan Botanee Bio-Technology Group Co.LTD wie ein Experte! Dieser DCF-Taschenrechner (300957SZ) enthält vorgefüllte Finanzdaten und ermöglicht Ihnen die vollständige Kontrolle über die Änderung des Umsatzwachstums, der WACC, der Margen und anderer wesentlicher Annahmen, um sich an Ihren Projektionen anzupassen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,636.5 | 4,022.4 | 5,013.9 | 5,522.2 | 5,735.9 | 6,487.0 | 7,336.4 | 8,297.1 | 9,383.6 | 10,612.4 |
| Revenue Growth, % | 0 | 52.57 | 24.65 | 10.14 | 3.87 | 13.09 | 13.09 | 13.09 | 13.09 | 13.09 |
| EBITDA | 663.7 | 1,095.5 | 1,309.2 | 1,011.7 | 815.8 | 1,440.9 | 1,629.6 | 1,843.0 | 2,084.3 | 2,357.3 |
| EBITDA, % | 25.17 | 27.23 | 26.11 | 18.32 | 14.22 | 22.21 | 22.21 | 22.21 | 22.21 | 22.21 |
| Depreciation | 24.9 | 73.4 | 91.9 | 137.9 | 189.8 | 135.0 | 152.7 | 172.7 | 195.3 | 220.9 |
| Depreciation, % | 0.94374 | 1.82 | 1.83 | 2.5 | 3.31 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 |
| EBIT | 638.8 | 1,022.1 | 1,217.3 | 873.8 | 626.0 | 1,305.9 | 1,476.9 | 1,670.3 | 1,889.0 | 2,136.4 |
| EBIT, % | 24.23 | 25.41 | 24.28 | 15.82 | 10.91 | 20.13 | 20.13 | 20.13 | 20.13 | 20.13 |
| Total Cash | 752.0 | 2,815.8 | 3,947.9 | 3,639.8 | 4,238.7 | 4,113.7 | 4,652.4 | 5,261.6 | 5,950.6 | 6,729.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 326.5 | 328.3 | 570.0 | 742.9 | 1,083.7 | 833.7 | 942.9 | 1,066.4 | 1,206.0 | 1,363.9 |
| Account Receivables, % | 12.38 | 8.16 | 11.37 | 13.45 | 18.89 | 12.85 | 12.85 | 12.85 | 12.85 | 12.85 |
| Inventories | 253.7 | 463.3 | 670.7 | 904.4 | 611.9 | 798.7 | 903.3 | 1,021.6 | 1,155.4 | 1,306.7 |
| Inventories, % | 9.62 | 11.52 | 13.38 | 16.38 | 10.67 | 12.31 | 12.31 | 12.31 | 12.31 | 12.31 |
| Accounts Payable | 134.8 | 361.6 | 372.4 | 401.9 | 447.2 | 474.9 | 537.1 | 607.4 | 687.0 | 776.9 |
| Accounts Payable, % | 5.11 | 8.99 | 7.43 | 7.28 | 7.8 | 7.32 | 7.32 | 7.32 | 7.32 | 7.32 |
| Capital Expenditure | -89.5 | -270.7 | -353.4 | -274.3 | -378.4 | -372.8 | -421.6 | -476.8 | -539.3 | -609.9 |
| Capital Expenditure, % | -3.39 | -6.73 | -7.05 | -4.97 | -6.6 | -5.75 | -5.75 | -5.75 | -5.75 | -5.75 |
| Tax Rate, % | 17.32 | 17.32 | 17.32 | 17.32 | 17.32 | 17.32 | 17.32 | 17.32 | 17.32 | 17.32 |
| EBITAT | 536.0 | 866.5 | 1,054.3 | 761.1 | 517.6 | 1,110.2 | 1,255.6 | 1,420.0 | 1,605.9 | 1,816.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 26.0 | 684.6 | 354.3 | 247.7 | 326.0 | 963.3 | 835.1 | 944.4 | 1,068.1 | 1,208.0 |
| WACC, % | 6.92 | 6.93 | 6.93 | 6.93 | 6.92 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 4,085.2 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 1,250 | |||||||||
| Terminal Value | 36,491 | |||||||||
| Present Terminal Value | 26,108 | |||||||||
| Enterprise Value | 30,193 | |||||||||
| Net Debt | -1,056 | |||||||||
| Equity Value | 31,249 | |||||||||
| Diluted Shares Outstanding, MM | 419 | |||||||||
| Equity Value Per Share | 74.54 |
What You Will Receive
- Comprehensive Financial Model: Utilize Yunnan Botanee Bio-Technology Group Co. LTD's actual data for accurate DCF valuation.
- Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other critical factors.
- Real-Time Calculations: Automatic updates allow for immediate visibility of results as adjustments are made.
- Professional-Grade Template: An expertly crafted Excel file designed for top-tier valuation standards.
- Flexible and Reusable: Designed for adaptability, enabling multiple uses for in-depth forecasts.
Key Features
- Real-Time Yunnan Botanee Data: Pre-loaded with historical financial data and future projections for Yunnan Botanee Bio-Technology Group Co. LTD (300957SZ).
- Customizable Inputs: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditures to suit your analysis.
- Interactive Valuation Model: Automatic computation of Net Present Value (NPV) and intrinsic value in response to your specified parameters.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different potential valuation results.
- User-Friendly Interface: Intuitive, organized, and crafted for both seasoned professionals and newcomers.
How It Works
- Step 1: Download the Excel file for Yunnan Botanee Bio-Technology Group Co.LTD (300957SZ).
- Step 2: Review the pre-filled financial data and forecasts specific to Yunnan Botanee.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch as the DCF model updates in real-time based on your adjustments.
- Step 5: Evaluate the outputs and leverage the results for informed investment decisions.
Why Choose This Calculator for Yunnan Botanee Bio-Technology Group Co. LTD (300957SZ)?
- Designed for Experts: An advanced tool utilized by industry analysts, financial officers, and consultants.
- Accurate Data: Yunnan Botanee's historical and projected financials are pre-loaded for enhanced precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Comprehensive Outputs: Instantly computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Detailed step-by-step guidance makes the process straightforward.
Who Can Benefit from Our Product?
- Investors: Make informed decisions with our advanced valuation tools tailored for the biotechnology sector.
- Financial Analysts: Streamline your workflow with our customizable DCF model designed for the unique needs of biotech firms like Yunnan Botanee Bio-Technology Group Co. LTD (300957SZ).
- Consultants: Effortlessly modify the template for impactful client presentations or detailed reports.
- Biotech Enthusiasts: Expand your knowledge of valuation methodologies through real-life case studies from the biotechnology industry.
- Educators and Students: Utilize it as a hands-on learning resource in finance and biotechnology courses.
Contents of the Template
- Preloaded Yunnan Botanee Data: Historical and projected financial information, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets designed for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financials for in-depth analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to assess performance.
- Dashboard and Charts: Visual representations of valuation results and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.